(-)-demecolcine decreases expression ISO RGD:1321067 6480464 Demecolcine results in decreased expression of TFAP2A mRNA CTD PMID:23649840 1,2-dimethylhydrazine increases expression EXP 6480464 1, 2-Dimethylhydrazine results in increased expression of TFAP2A mRNA CTD PMID:22206623 14-Deoxy-11,12-didehydroandrographolide increases expression ISO RGD:1321067 6480464 14-deoxy-11, 12-didehydroandrographolide results in increased expression of TFAP2A mRNA CTD PMID:22101062 15-acetyldeoxynivalenol increases expression ISO RGD:1321067 6480464 15-acetyldeoxynivalenol results in increased expression of TFAP2A mRNA CTD PMID:23792671 17beta-estradiol decreases expression ISO RGD:1321067 6480464 Estradiol results in decreased expression of TFAP2A mRNA CTD PMID:26865669 , PMID:28711546 2,2',4,4'-Tetrabromodiphenyl ether increases expression ISO RGD:1321067 6480464 2 more ... CTD PMID:31326446 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of TFAP2A mRNA CTD PMID:21570461 , PMID:24058054 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1310267 6480464 Tetrachlorodibenzodioxin results in decreased expression of TFAP2A mRNA CTD PMID:33387578 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1321067 6480464 Tetrachlorodibenzodioxin results in increased expression of TFAP2A mRNA CTD PMID:19901195 more ... 2,3,7,8-tetrachlorodibenzodioxine multiple interactions EXP 6480464 TFAP2A mRNA affects the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein] CTD PMID:16085934 3,3',5,5'-tetrabromobisphenol A increases expression ISO RGD:1321067 6480464 tetrabromobisphenol A results in increased expression of TFAP2A mRNA CTD PMID:31326446 3-isobutyl-1-methyl-7H-xanthine multiple interactions EXP 6480464 [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of TFAP2A mRNA, Acrylamide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of TFAP2A mRNA] CTD PMID:30409764 4,4'-sulfonyldiphenol decreases expression EXP 6480464 bis(4-hydroxyphenyl)sulfone results in decreased expression of TFAP2A mRNA CTD PMID:30951980 4,4'-sulfonyldiphenol decreases methylation EXP 6480464 bis(4-hydroxyphenyl)sulfone results in decreased methylation of TFAP2A promoter CTD PMID:33297965 4-[3-(4-tert-butylphenyl)-2-methylpropyl]-2,6-dimethylmorpholine increases expression EXP 6480464 fenpropimorph results in increased expression of TFAP2A protein CTD PMID:34737147 4-hydroxyphenyl retinamide increases expression EXP 6480464 Fenretinide results in increased expression of TFAP2A mRNA CTD PMID:28973697 5-aza-2'-deoxycytidine increases expression ISO RGD:1321067 6480464 Decitabine results in increased expression of TFAP2A mRNA, Decitabine results in increased expression of TFAP2A protein CTD PMID:16204029 5-aza-2'-deoxycytidine multiple interactions ISO RGD:1321067 6480464 [Decitabine results in increased expression of TFAP2A protein] which results in increased susceptibility to Cisplatin, [Decitabine results in increased expression of TFAP2A protein] which results in increased susceptibility to Doxorubicin CTD PMID:16204029 6-propyl-2-thiouracil increases expression ISO RGD:1310267 6480464 Propylthiouracil results in increased expression of TFAP2A mRNA CTD PMID:24780913 acrylamide multiple interactions EXP 6480464 Acrylamide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of TFAP2A mRNA], Acrylamide promotes the reaction [Dietary Fats results in increased expression of TFAP2A mRNA] CTD PMID:30409764 afimoxifene decreases expression ISO RGD:1321067 6480464 afimoxifene results in decreased expression of TFAP2A mRNA CTD PMID:19901195 aflatoxin B1 decreases methylation ISO RGD:1321067 6480464 Aflatoxin B1 results in decreased methylation of TFAP2A gene CTD PMID:27153756 all-trans-retinoic acid multiple interactions ISO RGD:1321067 6480464 Tretinoin inhibits the reaction [TFAP2A protein binds to DPYSL2 promoter] more ... CTD PMID:17229153 , PMID:17318229 all-trans-retinoic acid increases expression ISO RGD:1321067 6480464 Tretinoin results in increased expression of TFAP2A mRNA CTD PMID:17138961 more ... all-trans-retinoic acid affects localization ISO RGD:1321067 6480464 Tretinoin affects the localization of TFAP2A protein CTD PMID:17229153 antimycin A decreases expression ISO RGD:1321067 6480464 Antimycin A results in decreased expression of TFAP2A mRNA CTD PMID:33512557 antirheumatic drug decreases expression ISO RGD:1321067 6480464 Antirheumatic Agents results in decreased expression of TFAP2A mRNA CTD PMID:24449571 arotinoid acid multiple interactions ISO RGD:1321067 6480464 [4-(2-(5 more ... CTD PMID:34480604 arsenite(3-) decreases methylation ISO RGD:1321067 6480464 arsenite results in decreased methylation of TFAP2A promoter CTD PMID:23974009 belinostat increases expression ISO RGD:1321067 6480464 belinostat results in increased expression of TFAP2A mRNA CTD PMID:26272509 belinostat multiple interactions ISO RGD:1321067 6480464 [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA CTD PMID:27188386 benzo[a]pyrene decreases expression EXP 6480464 Benzo(a)pyrene results in decreased expression of TFAP2A mRNA CTD PMID:22228805 benzo[a]pyrene increases expression ISO RGD:1321067 6480464 Benzo(a)pyrene results in increased expression of TFAP2A mRNA CTD PMID:32234424 benzo[a]pyrene decreases methylation ISO RGD:1321067 6480464 Benzo(a)pyrene results in decreased methylation of TFAP2A 3' UTR more ... CTD PMID:27901495 benzo[a]pyrene diol epoxide I increases expression ISO RGD:1321067 6480464 7 more ... CTD PMID:17944540 benzo[a]pyrene diol epoxide I decreases expression ISO RGD:1321067 6480464 7 more ... CTD PMID:19150397 , PMID:20018196 bisphenol A decreases expression ISO RGD:1310267 6480464 bisphenol A results in decreased expression of TFAP2A mRNA CTD PMID:25181051 bisphenol A multiple interactions ISO RGD:1321067 6480464 [bisphenol A co-treated with Fulvestrant] results in decreased methylation of TFAP2A gene CTD PMID:31601247 bisphenol A affects methylation EXP 6480464 bisphenol A affects the methylation of TFAP2A promoter CTD PMID:27334623 Bisphenol A diglycidyl ether multiple interactions EXP 6480464 2, 2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Cytarabine results in increased expression of TFAP2A mRNA] CTD PMID:23264188 bisphenol F decreases expression EXP 6480464 bisphenol F results in decreased expression of TFAP2A mRNA CTD PMID:30951980 butan-1-ol multiple interactions ISO RGD:1321067 6480464 [[Gasoline co-treated with 1-Butanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TFAP2A mRNA CTD PMID:29432896 butanal decreases expression ISO RGD:1321067 6480464 butyraldehyde results in decreased expression of TFAP2A mRNA CTD PMID:26079696 Butylbenzyl phthalate affects localization ISO RGD:1321067 6480464 butylbenzyl phthalate affects the localization of TFAP2A protein CTD PMID:22552774 Butylbenzyl phthalate multiple interactions ISO RGD:1321067 6480464 [butylbenzyl phthalate promotes the reaction [TFAP2A protein binds to HDAC6 promoter]] which results in increased expression of HDAC6 mRNA more ... CTD PMID:22552774 cadmium atom decreases activity EXP 6480464 Cadmium results in decreased activity of TFAP2A protein CTD PMID:33642518 calcitriol increases expression ISO RGD:1321067 6480464 Calcitriol results in increased expression of TFAP2A mRNA CTD PMID:26485663 cannabidiol multiple interactions EXP 6480464 T 0070907 inhibits the reaction [Cannabidiol analog results in increased expression of TFAP2A mRNA] CTD PMID:30382123 cannabidiol increases expression EXP 6480464 Cannabidiol analog results in increased expression of TFAP2A mRNA CTD PMID:30382123 carboplatin increases response to substance ISO RGD:1321067 6480464 TFAP2A protein results in increased susceptibility to Carboplatin CTD PMID:16204029 CHIR 99021 multiple interactions ISO RGD:1321067 6480464 [4-(2-(5 more ... CTD PMID:34480604 chlorpyrifos decreases expression EXP 6480464 Chlorpyrifos results in decreased expression of TFAP2A mRNA CTD PMID:32715474 choline multiple interactions EXP 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of TFAP2A gene CTD PMID:20938992 cidofovir anhydrous decreases expression ISO RGD:1321067 6480464 Cidofovir results in decreased expression of TFAP2A mRNA CTD PMID:25596134 cisplatin increases expression ISO RGD:1321067 6480464 Cisplatin results in increased expression of TFAP2A protein CTD PMID:16204029 cisplatin decreases expression ISO RGD:1321067 6480464 Cisplatin results in decreased expression of TFAP2A mRNA CTD PMID:25596134 cisplatin increases response to substance ISO RGD:1321067 6480464 TFAP2A protein results in increased susceptibility to Cisplatin CTD PMID:16204029 , PMID:21489314 cisplatin affects response to substance ISO RGD:1321067 6480464 TFAP2A protein affects the susceptibility to Cisplatin CTD PMID:16217747 cisplatin multiple interactions ISO RGD:1321067 6480464 [decitabine results in increased expression of TFAP2A protein] which results in increased susceptibility to Cisplatin, [TFAP2A protein co-treated with TP53 gene mutant form] results in decreased susceptibility to Cisplatin CTD PMID:16204029 , PMID:21489314 clodronic acid decreases expression ISO RGD:1321067 6480464 Clodronic Acid results in decreased expression of TFAP2A mRNA CTD PMID:25596134 clomiphene increases expression ISO RGD:1321067 6480464 Clomiphene results in increased expression of TFAP2A mRNA CTD PMID:26865669 cortisol multiple interactions ISO RGD:1321067 6480464 [4-(2-(5 more ... CTD PMID:34480604 coumarin increases phosphorylation ISO RGD:1321067 6480464 coumarin results in increased phosphorylation of TFAP2A protein CTD PMID:35688186 Cuprizon increases expression ISO RGD:1310267 6480464 Cuprizone results in increased expression of TFAP2A mRNA CTD PMID:27523638 cycloheximide decreases stability ISO RGD:1321067 6480464 Cycloheximide results in decreased stability of TFAP2A protein CTD PMID:36576707 cycloheximide multiple interactions ISO RGD:1321067 6480464 LINC-ROR promotes the reaction [Cycloheximide results in decreased stability of TFAP2A protein] CTD PMID:36576707 cyclosporin A decreases expression ISO RGD:1321067 6480464 Cyclosporine results in decreased expression of TFAP2A mRNA CTD PMID:25596134 cytarabine multiple interactions EXP 6480464 2, 2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Cytarabine results in increased expression of TFAP2A mRNA] CTD PMID:23264188 cytarabine increases expression EXP 6480464 Cytarabine results in increased expression of TFAP2A mRNA CTD PMID:23264188 decabromodiphenyl ether increases expression ISO RGD:1321067 6480464 decabromobiphenyl ether results in increased expression of TFAP2A mRNA CTD PMID:31326446 dexamethasone multiple interactions EXP 6480464 [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of TFAP2A mRNA, Acrylamide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of TFAP2A mRNA] CTD PMID:30409764 dibutyl phthalate affects localization ISO RGD:1321067 6480464 Dibutyl Phthalate affects the localization of TFAP2A protein CTD PMID:22552774 dibutyl phthalate multiple interactions ISO RGD:1321067 6480464 [Dibutyl Phthalate promotes the reaction [TFAP2A protein binds to HDAC6 promoter]] which results in increased expression of HDAC6 mRNA more ... CTD PMID:22552774 diethylstilbestrol decreases expression ISO RGD:1321067 6480464 Diethylstilbestrol results in decreased expression of TFAP2A mRNA CTD PMID:26865669 dorsomorphin multiple interactions ISO RGD:1321067 6480464 [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin multiple interactions ISO RGD:1321067 6480464 [decitabine results in increased expression of TFAP2A protein] which results in increased susceptibility to Doxorubicin CTD PMID:16204029 doxorubicin increases response to substance ISO RGD:1321067 6480464 TFAP2A protein results in increased susceptibility to Doxorubicin CTD PMID:16204029 doxorubicin increases expression ISO RGD:1321067 6480464 Doxorubicin results in increased expression of TFAP2A protein CTD PMID:16204029 entinostat increases expression ISO RGD:1321067 6480464 entinostat results in increased expression of TFAP2A mRNA CTD PMID:26272509 entinostat multiple interactions ISO RGD:1321067 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA CTD PMID:27188386 erlotinib hydrochloride multiple interactions ISO RGD:1321067 6480464 Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter], Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]] CTD PMID:21499124 , PMID:21951556 ethanol increases expression ISO RGD:1321067 6480464 Ethanol results in increased expression of TFAP2A mRNA CTD PMID:28986285 etoposide affects response to substance ISO RGD:1321067 6480464 TFAP2A protein affects the susceptibility to Etoposide CTD PMID:16217747 etoposide increases response to substance ISO RGD:1321067 6480464 TFAP2A protein results in increased susceptibility to Etoposide CTD PMID:16204029 fenpropidin increases expression EXP 6480464 fenpropidine results in increased expression of TFAP2A protein CTD PMID:34737147 flusilazole increases expression EXP 6480464 flusilazole results in increased expression of TFAP2A mRNA, flusilazole results in increased expression of TFAP2A protein CTD PMID:34737147 folic acid multiple interactions EXP 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of TFAP2A gene CTD PMID:20938992 fulvestrant increases expression ISO RGD:1321067 6480464 fulvestrant results in increased expression of TFAP2A mRNA CTD PMID:26865669 fulvestrant multiple interactions ISO RGD:1321067 6480464 [bisphenol A co-treated with Fulvestrant] results in decreased methylation of TFAP2A gene CTD PMID:31601247 furan increases expression ISO RGD:1310267 6480464 furan results in increased expression of TFAP2A mRNA CTD PMID:25539665 gefitinib multiple interactions ISO RGD:1321067 6480464 gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter], Tetradecanoylphorbol Acetate inhibits the reaction [gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]] CTD PMID:21499124 , PMID:21951556 gemcitabine increases response to substance ISO RGD:1321067 6480464 TFAP2A protein results in increased susceptibility to Gemcitabine CTD PMID:21489314 gemcitabine multiple interactions ISO RGD:1321067 6480464 [TFAP2A protein co-treated with TP53 gene mutant form] results in decreased susceptibility to Gemcitabine CTD PMID:21489314 genistein decreases expression ISO RGD:1321067 6480464 Genistein results in decreased expression of TFAP2A mRNA CTD PMID:26865669 gentamycin decreases expression ISO RGD:1310267 6480464 Gentamicins results in decreased expression of TFAP2A mRNA CTD PMID:33387578 geraniol increases expression ISO RGD:1321067 6480464 geraniol results in increased expression of TFAP2A mRNA CTD PMID:27683099 hexestrol decreases expression ISO RGD:1321067 6480464 Hexestrol results in decreased expression of TFAP2A mRNA CTD PMID:26865669 ifosfamide decreases expression ISO RGD:1321067 6480464 Ifosfamide results in decreased expression of TFAP2A mRNA CTD PMID:25596134 indinavir decreases expression EXP 6480464 Indinavir results in decreased expression of TFAP2A mRNA CTD PMID:17926646 kahweol decreases expression ISO RGD:1321067 6480464 kahweol results in decreased expression of TFAP2A mRNA, kahweol results in decreased expression of TFAP2A protein CTD PMID:30205135 L-ascorbic acid multiple interactions ISO RGD:1321067 6480464 [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA CTD PMID:34480604 L-ascorbic acid 2-phosphate multiple interactions ISO RGD:1321067 6480464 [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA CTD PMID:34480604 L-methionine multiple interactions EXP 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of TFAP2A gene CTD PMID:20938992 lipopolysaccharide increases expression ISO RGD:1321067 6480464 Lipopolysaccharides results in increased expression of TFAP2A mRNA CTD PMID:35811015 lipopolysaccharide multiple interactions ISO RGD:1321067 6480464 S-(1, 2-dichlorovinyl)cysteine inhibits the reaction [Lipopolysaccharides results in increased expression of TFAP2A mRNA] CTD PMID:35811015 manganese atom increases expression ISO RGD:1310267 6480464 Manganese results in increased expression of TFAP2A protein CTD PMID:24845367 manganese(0) increases expression ISO RGD:1310267 6480464 Manganese results in increased expression of TFAP2A protein CTD PMID:24845367 mercury dibromide increases expression ISO RGD:1321067 6480464 mercuric bromide results in increased expression of TFAP2A mRNA CTD PMID:26272509 mercury dibromide multiple interactions ISO RGD:1321067 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA CTD PMID:27188386 mestranol decreases expression ISO RGD:1321067 6480464 Mestranol results in decreased expression of TFAP2A mRNA CTD PMID:26865669 methamphetamine increases expression ISO RGD:1310267 6480464 Methamphetamine results in increased expression of TFAP2A mRNA CTD PMID:28341135 methotrexate affects expression EXP 6480464 Methotrexate affects the expression of TFAP2A mRNA CTD PMID:18502557 methylmercury chloride increases expression ISO RGD:1321067 6480464 methylmercuric chloride results in increased expression of TFAP2A mRNA CTD PMID:23179753 , PMID:26272509 methylmercury chloride decreases expression ISO RGD:1321067 6480464 methylmercuric chloride results in decreased expression of TFAP2A mRNA CTD PMID:28001369 methylparaben decreases expression ISO RGD:1321067 6480464 methylparaben results in decreased expression of TFAP2A mRNA CTD PMID:31745603 mitomycin C affects response to substance ISO RGD:1321067 6480464 TFAP2A protein affects the susceptibility to Mitomycin CTD PMID:16217747 N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide multiple interactions ISO RGD:1321067 6480464 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [butylbenzyl phthalate affects the localization of TFAP2A protein], N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dibutyl Phthalate affects the localization of TFAP2A protein] CTD PMID:22552774 nickel subsulfide decreases expression ISO RGD:1321067 6480464 nickel subsulfide results in decreased expression of TFAP2A mRNA CTD PMID:12760830 ozone multiple interactions ISO RGD:1321067 6480464 Ozone promotes the reaction [TFAP2A protein binds to BRS3 promoter], TFAP2A protein affects the reaction [Ozone results in increased expression of BRS3 mRNA] CTD PMID:17355223 ozone increases activity ISO RGD:1321067 6480464 Ozone results in increased activity of TFAP2A protein CTD PMID:17355223 p-chloromercuribenzoic acid increases expression ISO RGD:1321067 6480464 p-Chloromercuribenzoic Acid results in increased expression of TFAP2A mRNA CTD PMID:26272509 p-chloromercuribenzoic acid multiple interactions ISO RGD:1321067 6480464 [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA CTD PMID:27188386 paclitaxel increases response to substance ISO RGD:1321067 6480464 TFAP2A protein results in increased susceptibility to Paclitaxel CTD PMID:16204029 paclitaxel increases expression ISO RGD:1321067 6480464 Paclitaxel results in increased expression of TFAP2A protein CTD PMID:16204029 panobinostat multiple interactions ISO RGD:1321067 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA CTD PMID:27188386 panobinostat increases expression ISO RGD:1321067 6480464 panobinostat results in increased expression of TFAP2A mRNA CTD PMID:26272509 paracetamol decreases expression ISO RGD:1321067 6480464 Acetaminophen results in decreased expression of TFAP2A mRNA CTD PMID:26690555 paracetamol increases expression ISO RGD:1321067 6480464 Acetaminophen results in increased expression of TFAP2A mRNA CTD PMID:29067470 paraquat increases expression ISO RGD:1321067 6480464 Paraquat results in increased expression of TFAP2A mRNA CTD PMID:35182771 paroxetine increases expression ISO RGD:1321067 6480464 Paroxetine results in increased expression of TFAP2A protein CTD PMID:28844482 phenylmercury acetate increases expression ISO RGD:1321067 6480464 Phenylmercuric Acetate results in increased expression of TFAP2A mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:1321067 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA CTD PMID:27188386 phorbol 13-acetate 12-myristate multiple interactions ISO RGD:1321067 6480464 Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]], Tetradecanoylphorbol Acetate inhibits the reaction [gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]] CTD PMID:21499124 , PMID:21951556 picoxystrobin decreases expression ISO RGD:1321067 6480464 picoxystrobin results in decreased expression of TFAP2A mRNA CTD PMID:33512557 pirinixic acid increases expression EXP 6480464 pirinixic acid results in increased expression of TFAP2A mRNA CTD PMID:18445702 raloxifene increases expression ISO RGD:1321067 6480464 Raloxifene Hydrochloride results in increased expression of TFAP2A mRNA CTD PMID:26865669 resveratrol multiple interactions ISO RGD:1321067 6480464 resveratrol results in increased localization of and results in increased activity of TFAP2A protein CTD PMID:16488535 rotenone decreases expression ISO RGD:1321067 6480464 Rotenone results in decreased expression of TFAP2A mRNA CTD PMID:33512557 rottlerin multiple interactions ISO RGD:1321067 6480464 rottlerin inhibits the reaction [TFAP2A protein binds to ULBP1 promoter] CTD PMID:21499124 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions ISO RGD:1321067 6480464 S-(1, 2-dichlorovinyl)cysteine inhibits the reaction [Lipopolysaccharides results in increased expression of TFAP2A mRNA] CTD PMID:35811015 SB 431542 multiple interactions ISO RGD:1321067 6480464 [LDN 193189 co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 , PMID:34480604 sertraline increases expression ISO RGD:1321067 6480464 Sertraline results in increased expression of TFAP2A protein CTD PMID:28844482 spiroxamine increases expression EXP 6480464 spiroxamine results in increased expression of TFAP2A protein CTD PMID:34737147 stavudine decreases expression EXP 6480464 Stavudine results in decreased expression of TFAP2A mRNA CTD PMID:17926646 streptozocin multiple interactions ISO RGD:1310267 6480464 MFN2 protein mutant form inhibits the reaction [Streptozocin promotes the reaction [TFAP2A protein binds to COL4A1 promoter]], Streptozocin promotes the reaction [TFAP2A protein binds to COL4A1 promoter] CTD PMID:27997345 temozolomide increases expression ISO RGD:1321067 6480464 Temozolomide results in increased expression of TFAP2A mRNA CTD PMID:31758290 testosterone decreases expression ISO RGD:1321067 6480464 Testosterone results in decreased expression of TFAP2A mRNA CTD PMID:33359661 Tetrachlorobisphenol A increases expression ISO RGD:1321067 6480464 tetrachlorodian results in increased expression of TFAP2A mRNA CTD PMID:31326446 trichloroethene increases expression EXP 6480464 Trichloroethylene results in increased expression of TFAP2A mRNA CTD PMID:21135412 trichostatin A increases expression ISO RGD:1321067 6480464 trichostatin A results in increased expression of TFAP2A mRNA CTD PMID:24935251 , PMID:26272509 trichostatin A multiple interactions ISO RGD:1321067 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA CTD PMID:27188386 triclosan decreases expression ISO RGD:1321067 6480464 Triclosan results in decreased expression of TFAP2A mRNA CTD PMID:30510588 troglitazone multiple interactions ISO RGD:1321067 6480464 [Troglitazone co-treated with 4-((3-bromophenyl)amino)-6 more ... CTD PMID:32822399 troglitazone decreases expression ISO RGD:1321067 6480464 Troglitazone results in decreased expression of TFAP2A mRNA, Troglitazone results in decreased expression of TFAP2A protein CTD PMID:32822399 tyrphostin AG 1478 multiple interactions ISO RGD:1321067 6480464 RTKI cpd inhibits the reaction [butylbenzyl phthalate affects the localization of TFAP2A protein], RTKI cpd inhibits the reaction [Dibutyl Phthalate affects the localization of TFAP2A protein] CTD PMID:22552774 valproic acid decreases methylation ISO RGD:1321067 6480464 Valproic Acid results in decreased methylation of TFAP2A gene CTD PMID:29154799 valproic acid decreases expression EXP 6480464 Valproic Acid results in decreased expression of TFAP2A mRNA CTD PMID:31445079 valproic acid decreases expression ISO RGD:1321067 6480464 Valproic Acid results in decreased expression of TFAP2A mRNA CTD PMID:28001369 valproic acid multiple interactions ISO RGD:1321067 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 , PMID:32623605 valproic acid increases expression ISO RGD:1321067 6480464 Valproic Acid results in increased expression of TFAP2A mRNA CTD PMID:23179753 more ... valproic acid affects expression ISO RGD:1321067 6480464 Valproic Acid affects the expression of TFAP2A mRNA CTD PMID:25979313 valproic acid affects expression EXP 6480464 Valproic Acid affects the expression of TFAP2A mRNA CTD PMID:17292431 vincristine decreases expression ISO RGD:1321067 6480464 Vincristine results in decreased expression of TFAP2A mRNA CTD PMID:23649840 vorinostat multiple interactions ISO RGD:1321067 6480464 [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA CTD PMID:27188386 vorinostat increases expression ISO RGD:1321067 6480464 vorinostat results in increased expression of TFAP2A mRNA CTD PMID:26272509 XAV939 multiple interactions ISO RGD:1321067 6480464 [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA, [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA CTD PMID:34480604 zidovudine decreases expression EXP 6480464 Zidovudine results in decreased expression of TFAP2A mRNA CTD PMID:17926646
